Multiple Aspects of Gene Dysregulation in Huntington’s Disease

por Moumné, Lara, Betuing, Sandrine, Caboche, Jocelyne
Publicado 2013

Oligonucleotide Therapeutics: From Discovery and Development to Patentability

por Moumné, Lara, Marie, Anne-Céline, Crouvezier, Nicolas
Publicado 2022

Genetic Knock-Down of Hdac3 Does Not Modify Disease-Related Phenotypes in a Mouse Model of Huntington's Disease

por Moumné, Lara, Campbell, Ken, Howland, David, Ouyang, Yingbin, Bates, Gillian P.
Publicado 2012

CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease

por Boussicault, Lydie, Alves, Sandro, Lamazière, Antonin, Planques, Anabelle, Heck, Nicolas, Moumné, Lara, Despres, Gaëtan, Bolte, Susanne, Hu, Amélie, Pagès, Christiane, Galvan, Laurie, Piguet, Francoise, Aubourg, Patrick, Cartier, Nathalie, Caboche, Jocelyne, Betuing, Sandrine
Publicado 2016

Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo

por Beconi, Maria, Aziz, Omar, Matthews, Kim, Moumné, Lara, O’Connell, Catherine, Yates, Dawn, Clifton, Steven, Pett, Hannah, Vann, Julie, Crowley, Lynsey, Haughan, Alan F., Smith, Donna L., Woodman, Ben, Bates, Gillian P., Brookfield, Fred, Bürli, Roland W., McAllister, George, Dominguez, Celia, Munoz-Sanjuan, Ignacio, Beaumont, Vahri
Publicado 2012